<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Deferiprone: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Deferiprone: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Deferiprone: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="17092" href="/d/html/17092.html" rel="external">see "Deferiprone: Drug information"</a> and <a class="drug drug_patient" data-topicid="17093" href="/d/html/17093.html" rel="external">see "Deferiprone: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F13301498"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Agranulocytosis/Neutropenia:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Deferiprone can cause agranulocytosis that can lead to serious infections and death. Neutropenia may precede the development of agranulocytosis. Measure the ANC before starting deferiprone therapy and monitor regularly while on therapy. Interrupt deferiprone therapy if neutropenia develops. Interrupt deferiprone therapy if infection develops and monitor the ANC more frequently. Advise patients taking deferiprone to report immediately any symptoms indicative of infection.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F13688783"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Ferriprox;</li>
<li>Ferriprox Twice-A-Day</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871399"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Ferriprox;</li>
<li>Ferriprox MR</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F55869121"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Chelating Agent</span></li></ul></div>
<div class="block dop drugH1Div" id="F55869126"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Deferiprone is available as an oral solution, a 500 mg tablet, and as 2 different 1,000 mg tablet formulations (a twice-a-day formulation and a 3-times-a-day formulation); verify formulation prior to ordering/dispensing to avoid medication errors. <b>Use actual body weight for dose calculations.</b></p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="aefcbbd7-82f0-4434-b7dd-969b3f1a5b88">Transfusional iron overload, secondary thalassemia syndromes and sickle cell disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Transfusional</b>
<b> iron overload, secondary thalassemia syndromes and sickle cell disease:</b>
<b>Note:</b> Has been used as monotherapy or in combination with other oral iron chelating agents; patients should be closely monitored for neutropenia; in trials, ANC was assessed weekly or at least prior to every transfusion (Gomber 2018; Maggio 2020; Nazir 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initial dosing:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Children &lt;8 years: Limited data available in ages &lt;3 years: Oral solution: Oral: 25 mg/kg/dose 3 times daily; round dose to the nearest 250 mg (2.5 mL); may consider a lower dose of 15 mg/kg/dose 3 times a day titrated in 15 mg/kg increments at weekly intervals to minimize GI side effects when initiating therapy (Botzenhardt 2018; Maggio 2020; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥8 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">Three-times-daily dosing:</p>
<p style="text-indent:-2em;margin-left:10em;">Oral solution, 3-times-daily 500 mg or 1,000 mg tablet formulations: Oral: Initial: 25 mg/kg/dose 3 times daily; for oral solution, round dose to the nearest 250 mg (2.5 mL); for tablets, round dose to the nearest <sup>1</sup>/<sub>2</sub> tablet; may consider a lower initial dose of 15 mg/kg/dose 3 times a day titrated in 15 mg/kg increments at weekly intervals to minimize GI side effects when initiating therapy.</p>
<p style="text-indent:-2em;margin-left:8em;">Two-times-daily dosing:</p>
<p style="text-indent:-2em;margin-left:10em;">Twice-daily 1,000 mg tablet formulation: Oral: Initial: 37.5 mg/kg/dose every 12 hours; round dose to the nearest 500 mg; may consider a lower dose of 22.5 mg/kg/dose every 12 hours titrated in 15 mg/kg increments at weekly intervals to minimize GI side effects when initiating therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Maintenance dosing: </i>Children and Adolescents: Monitor serum ferritin every 2 to 3 months with therapy per the manufacturer; individualize dose based on response and therapeutic goals for hemoglobinopathy; not to exceed maximum daily dose: 99 to 100 mg/kg/<b>day</b> (Maggio 2020; manufacturer's labeling). In DEEP-2 trial, serum ferritin was assessed monthly (Maggio 2020). If serum ferritin falls consistently below 500 mcg/L, consider temporary treatment interruption until serum ferritin rises above 500 mcg/L.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for toxicity: </b>Children and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">ANC 500<sup></sup>to &lt;1,500/mm<sup>3</sup>: Interrupt treatment immediately and monitor until recovery; do not rechallenge unless the potential benefit outweighs the risk.</p>
<p style="text-indent:-2em;margin-left:4em;">ANC &lt;500/mm<sup>3</sup>: In addition to treatment interruption, consider hospitalization (and other clinically-appropriate management); do not resume unless the potential benefits outweigh potential risks.</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Interrupt treatment; monitor ANC more frequently.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F55869129"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR ≥15 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied in pediatric patients). However, no clinically significant pharmacokinetic differences were observed in adult patients with eGFR 15 to 89 mL/minute/1.73 m<sup>2</sup>.</p>
<p style="text-indent:-2em;margin-left:4em;">End-stage renal disease: There are no dosage adjustments provided in the manufacturer's labeling (effect is unknown).</p></div>
<div class="block dohp drugH1Div" id="F55869130"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Baseline hepatic impairment:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Mild or moderate impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied in pediatric patients); however, no clinically significant pharmacokinetic differences were observed in adult patients with mild or moderate impairment; in clinical trials, pediatric patients with ALT &gt;5 × ULN were excluded (Maggio 2020).</p>
<p style="text-indent:-2em;margin-left:6em;">Severe impairment: There are no dosage adjustments provided in the manufacturer's labeling (effect is unknown).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hepatotoxicity during treatment:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Persistent increase in serum transaminase levels: Consider interruption of therapy; in pediatric clinical trials (DEEP-3), dosage adjustment could be utilized at an AST or ALT &gt;10 × ULN (Maggio 2020).</p></div>
<div class="block doa drugH1Div" id="F13301554"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="17092" href="/d/html/17092.html" rel="external">see "Deferiprone: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Round dose to the nearest 250 mg (or ½ of 500 mg tablet), 500 mg (or ½ of 1,000 mg tablet), or 2.5 mL (oral solution). If serum ferritin falls consistently below 500 mcg/L, consider temporary treatment interruption until serum ferritin rises above 500 mcg/L. Use actual body weight for dose calculation.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="26bdc96b-b588-4f59-8ed0-19a170bafe46">Transfusional iron overload</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Transfusional iron overload:</b>
<b>Oral:</b>
<b>Note:</b> Deferiprone is available as an oral solution, a 500 mg tablet, and as 2 different 1,000 mg tablet formulations (a twice-a-day formulation and a 3-times-a-day formulation); verify formulation prior to ordering/dispensing to avoid medication errors.</p>
<p style="text-indent:-2em;margin-left:4em;">Initial: 75 mg/kg/day in 2 divided doses (using 1,000 mg twice-a-day tablet formulation <b>only</b>) or in 3 divided doses (using oral solution, 500 mg tablet, or 1,000 mg 3-times-a-day tablet formulation); individualize dose based on response and therapeutic goal. Dosing may start at 45 mg/kg/day and be increased weekly by 15 mg/kg/day increments until 75 mg/kg/day is achieved to minimize GI upset.</p>
<p style="text-indent:-2em;margin-left:4em;">Maximum dose: 99 mg/kg/day.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990629"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">eGFR ≥15 mL/minute/1.73m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer's labeling. However, no clinically significant pharmacokinetic differences were observed in patients with eGFR 15 to 89 mL/minute/1.73m<sup>2</sup>.</p>
<p style="text-indent:-2em;margin-left:2em;">End stage renal disease: There are no dosage adjustments provided in the manufacturer's labeling (effect is unknown).</p></div>
<div class="block doha drugH1Div" id="F50987445"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic impairment prior to treatment initiation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Mild or moderate impairment (Child-Pugh class A or B): There are no dosage adjustments provided in the manufacturer's labeling. However, no clinically significant pharmacokinetic differences were observed in mild or moderate impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer's labeling (effect is unknown).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatotoxicity during treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Persistent increase in serum transaminase levels: Consider interruption of therapy.</p></div>
<div class="block adr drugH1Div" id="F13301518"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (thalassemia: ≤10%; sickle cell/anemias: 26%), nausea (7% to 13%), vomiting (10% to 19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (7% to 12%), increased serum aspartate aminotransferase (thalassemia: 1%; sickle cell/anemias: 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (thalassemia: 2%: sickle cell/anemias: 20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular and skeletal: Back pain (thalassemia: 2%; sickle cell/anemias: 13%), limb pain (thalassemia: 2%; sickle cell/anemias: 18%), ostealgia (sickle cell/anemias: 25%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (sickle cell/anemias: 28%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine and metabolic: Weight gain (thalassemia: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress (thalassemia: ≤10%), decreased appetite (thalassemia: 1%), diarrhea (3% to 5%), dyspepsia (thalassemia: 2%), increased appetite (thalassemia: 4%),</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (2%), neutropenia (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Pain (sickle cell/anemias: 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular and skeletal: Arthralgia (10%), arthropathy (thalassemia: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (sickle cell/anemias: 8%), nasopharyngitis (sickle cell/anemias: 9%), oropharyngeal pain (sickle cell/anemias: 10%), upper respiratory tract infection (sickle cell/anemias: 5%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined (all indications):</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum zinc</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urine discoloration</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (all indications):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial fibrillation, cardiac failure, hypertension, hypotension, peripheral edema, pulmonary embolism</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis, furuncle, pruritus, pustular rash, skin photosensitivity, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Bruxism, enterocolitis, gastric ulcer, pancreatitis, parotid gland enlargement</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration, glycosuria, metabolic acidosis</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hemoglobinuria, male hypospadias</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Henoch-Schönlein purpura, pancytopenia, rectal hemorrhage, thrombocythemia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis A, hepatomegaly, increased serum bilirubin, jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Cryptococcosis (cutaneous infection), sepsis, subcutaneous abscess</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal gait, cerebellar syndrome, cerebral hemorrhage, chills, depression, drowsiness, encephalitis (enteroviral), increased intracranial pressure, motor dysfunction (pyramidal tract syndrome), obsessive compulsive disorder, psychomotor impairment, seizure, trismus</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Chondrolysis of articular cartilage, increased creatine phosphokinase in blood specimen, myositis</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Diplopia, papilledema, periorbital edema, retinal toxicity</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Acute respiratory distress syndrome, epistaxis, hemoptysis, pharyngitis, pneumonia</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Multi-organ failure</p></div>
<div class="block coi drugH1Div" id="F13301503"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to deferiprone or any component of the formulation</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Severe neutropenia (ANC &lt;500/mm<sup>3</sup>); pregnancy; breastfeeding</p></div>
<div class="block war drugH1Div" id="F13301504"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Agranulocytosis/Neutropenia: May cause agranulocytosis, which could lead to serious infections (some fatal) and may be preceded by neutropenia. If ANC &lt;500/mm<sup>3</sup>, consider hospitalization (and other clinically appropriate management); do not resume or rechallenge unless the potential benefits outweigh potential risks. Neutropenia and agranulocytosis were generally reversible upon discontinuation. The mechanism for deferiprone-induced agranulocytosis is not known. Avoid concurrent use with other agents associated with neutropenia (or agranulocytosis).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Elevations in ALT values have been observed; consider treatment interruption for persistent ALT elevations.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions have been reported (eg, Henoch-Schönlein purpura [immunoglobulin A vasculitis], urticaria, and periorbital edema with skin rash).</p>
<p style="text-indent:-2em;margin-left:4em;">• Zinc deficiency: Lower plasma zinc concentrations have been observed; supplementation may be needed.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Tablets: Available in 2 different 1,000 mg formulations (a twice-a-day formulation and a 3-times-a-day formulation); each has different identifying characteristics. Ensure the tablet formulation is correct for the dosing regimen prior to prescribing and dispensing to prevent medication errors.</p></div>
<div class="block foc drugH1Div" id="F13307628"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ferriprox: 100 mg/mL (500 mL) [contains fd&amp;c yellow #6 (sunset yellow); cherry-peppermint flavor]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ferriprox: 500 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ferriprox: 500 mg [DSC] [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ferriprox: 1000 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ferriprox: 1000 mg [DSC] [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ferriprox Twice-A-Day: 1000 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ferriprox Twice-A-Day: 1000 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg, 1000 mg</p></div>
<div class="block geq drugH1Div" id="F20452823"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F16322919"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Ferriprox Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/mL (per mL): $21.02</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Deferiprone Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $73.81 - $82.26</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 mg (per each): $174.39</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Ferriprox Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $91.78</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 mg (per each): $183.57</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Ferriprox Twice-A-Day Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 mg (per each): $262.66</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871400"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ferriprox: 100 mg/mL (500 mL) [contains fd&amp;c yellow #6 (sunset yellow)]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ferriprox: 500 mg, 1000 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ferriprox MR: 1000 mg</p></div>
<div class="block admp drugH1Div" id="F55869132"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Deferiprone is available as an oral solution, a 500 mg tablet, and as 2 different 1,000 mg tablet formulations (a twice-a-day formulation and a 3-times-a-day formulation); verify formulation prior to administration to avoid medication errors. Tablets may be halved for necessary dose rounding.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: May consider taking with a meal to decrease nausea. Allow at least a 4-hour interval between deferiprone and medications or supplements containing polyvalent cations (eg, iron, aluminum, zinc).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral solution: Administer in the morning, at midday, and in the evening. Measure dose with provided cup; after dose administration, add 10 to 15 mL of water to the cup, swirl around to mix any remaining medication and consume. Hand wash measuring cup after use.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablets: Doses should be rounded to nearest half-tablet following verification of appropriate formulation.</p>
<p style="text-indent:-2em;margin-left:6em;">Three-times-daily formulation (500 or 1,000 mg): Administer in the morning, at midday, and in the evening.</p>
<p style="text-indent:-2em;margin-left:6em;">Twice-daily formulation (1,000 mg): Administer approximately every 12 hours (in the morning and evening).</p></div>
<div class="block adm drugH1Div" id="F13301559"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Deferiprone is available as an oral solution, a 500 mg tablet, and as 2 different 1,000 mg tablet formulations (a twice-a-day formulation and a 3-times-a-day formulation); verify formulation prior to administration to avoid medication errors.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Allow at least a 4-hour interval between deferiprone and medications or supplements containing polyvalent cations (eg, iron, aluminum, zinc).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral solution, 500 mg tablet, or 1,000 mg 3-times-a-day tablet formulation: Administer in the morning, at midday, and in the evening. Administration with food may decrease nausea.</p>
<p style="text-indent:-2em;margin-left:4em;">1,000 mg twice-a-day tablet formulation: Administer approximately every 12 hours (in the morning and evening) with food to decrease nausea/vomiting.</p></div>
<div class="block hazard drugH1Div" id="F49130979"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 2]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>
<div class="block sts drugH1Div" id="F13301541"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Store oral solution in original carton to protect from light; use contents within 35 days after first opening bottle; discard any remaining solution after 35 days.</p></div>
<div class="block meg drugH1Div" id="F14280404"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Ferriprox oral solution: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F208030s005lbl.pdf%23page%3D25&amp;token=DSuVtHE2viX7gt4ayXOWxzwXQpwr9X548YoDOALVOM7kBD4Wt0PPq5kVYS2yWagGbmUTyPbeHABrv4xW3%2BD8XgjEpgciVio6yvwzNGwT2xshkrsYm3%2BO1VJZyv%2FjwmhB&amp;TOPIC_ID=131933" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208030s005lbl.pdf#page=25</a></p>
<p style="text-indent:-2em;margin-left:4em;">Ferriprox tablets: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F212269s001lbl.pdf%23page%3D16&amp;token=%2BverorHVwTn4DHRahXtESSrDflL3%2BXsXAr8AZ730T3jBxn0%2Fe1i6FrrGvOj1%2BGsiqZcyNynxJIls6AMHSOaokbc1L5Y4PTiP5KnJltGsQX%2BmS7MHO87%2FjWOLU5Q5Epkb&amp;TOPIC_ID=131933" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212269s001lbl.pdf#page=16</a></p></div>
<div class="block usep drugH1Div" id="F55869124"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of transfusional iron overload due to thalassemia syndromes, sickle cell disease, or other anemias (excluding myelodysplastic syndrome or Diamond Blackfin anemia) (Oral solution: FDA approved in ages ≥3 years and adults; Tablets: FDA approved in ages ≥8 years and adults).</p></div>
<div class="block mst drugH1Div" id="F13299486"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Deferiprone may be confused with deferoxamine, deferasirox</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13301538"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of UGT1A6, UGT1A9, UGT2B15, UGT2B7</p></div>
<div class="block dri drugH1Div" id="F13320101"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May increase the serum concentration of Deferiprone.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Betibeglogene Autotemcel: Iron Chelators may diminish the therapeutic effect of Betibeglogene Autotemcel.  Management: Avoid use of iron chelators for at least 7 days prior to conditioning therapy preceding betibeglogene autotemcel treatment, and avoid use of myelosuppressive iron chelators for at least 6 months after betibeglogene autotemcel.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Exagamglogene Autotemcel: Iron Chelators may enhance the myelosuppressive effect of Exagamglogene Autotemcel. Iron Chelators may diminish the therapeutic effect of Exagamglogene Autotemcel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovotibeglogene Autotemcel: Iron Chelators may enhance the myelosuppressive effect of Lovotibeglogene Autotemcel. Iron Chelators may diminish the therapeutic effect of Lovotibeglogene Autotemcel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Myelosuppressive Agents: May enhance the neutropenic effect of Deferiprone. Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyvalent Cation Containing Products: May decrease the serum concentration of Deferiprone. Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">UGT1A6 Inhibitors: May increase the serum concentration of Deferiprone.<i> Risk X: Avoid combination</i></p></div>
<div class="block dic drugH1Div" id="F13307625"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Take with food to decrease nausea/vomiting. Allow at least a 4-hour interval with foods containing iron, aluminum, and zinc.</p></div>
<div class="block rep_considerations drugH1Div" id="F49297803"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Verify pregnancy status prior to initiation of deferiprone treatment. Females of reproductive potential should use contraception during treatment and for 6 months after the last deferiprone dose. Males with female partners of reproductive potential should use effective contraception during therapy and for 3 months after the last deferiprone dose.</p></div>
<div class="block pri drugH1Div" id="F13301500"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Based on data from animal reproduction studies, in utero exposure to deferiprone may cause fetal harm. Outcome information following deferiprone use in pregnancy is limited. Deferiprone should be discontinued if pregnancy occurs. When iron chelation therapy is needed in a pregnant woman, agents other than deferiprone are preferred (Diamantidis 2016; Origa 2019).</p></div>
<div class="block mopp drugH1Div" id="F55869133"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Serum ferritin (every 2 to 3 months); ANC (at baseline, weekly during treatment for the first 6 months of therapy, every 2 weeks for the next 6 months of therapy, and then every 2 to 4 weeks [or at the patient's blood transfusion interval if an interruption due to any ANC decrease has not occurred] thereafter; reduction in ANC monitoring may be considered on individual basis); if ANC &lt;1,500/mm<sup>3</sup>, monitor CBC, WBC (corrected for nucleated RBCs), ANC, and platelets daily until ANC recovery; ALT (at baseline and monthly); zinc levels (at baseline and regularly); signs or symptoms of infection; pregnancy status (prior to initiation and as clinically indicated).</p></div>
<div class="block pha drugH1Div" id="F13301542"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Iron-chelating agent with affinity for ferric ion (iron III); binds to ferric ion and forms a 3:1 (deferiprone:iron) complex which is excreted in the urine. Has a lower affinity for other metals such as copper, aluminum, and zinc.</p></div>
<div class="block phk drugH1Div" id="F13301545"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution:</p>
<p style="text-indent:-2em;margin-left:4em;">500 mg tablet: 1.6 L/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">1,000 mg tablet (twice-a-day formulation): 97 ± 28 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &lt;10%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily by UGT 1A6; major metabolite (3-O-glucuronide) lacks iron-binding capacity.</p>
<p style="text-indent:-2em;margin-left:2em;">Half life elimination: ~2 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: ~1 to 2 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (75% to 90%; primarily as metabolite).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F13733212"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Ferriprox</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Ferriprox</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Ferriprox</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Ferriprox</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Feripon</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Ferriprox</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Ferriprox</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Deferipron lipomed</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ferriprox</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Ferriprox</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Deferipron lipomed | Ferriprox</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Ferriprox</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Ferriprox</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Ferriprox</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Ferriprox</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Deferiprone arrow | Deferiprone lipomed | Ferriprox</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Deferiprone lipomed | Ferriprox</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Ferriprox</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Ferriprox</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Ferriprox | Oferlod</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Ferriprox</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Deferiprone doc | Deferiprone lipomed | Ferriprox</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Ferriprox</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Feriprox</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Ferriprox</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Deferiprone lipomed | Ferriprox</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Ferriprox</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Ferriprox</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Ferriprox</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Ferriprox | Gpo L One</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Ferriprox</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Ferriprox</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Apo Ferriprox</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Ferriprox</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Ferinil</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Ferriprox</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Ferriprox</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Ferriprox</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Ferriprox</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Ferriprox</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Ferriprox</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Deferipron | Ferriprox</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Ferriprox</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Ferriprox | Gpo L One</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Ferriprox</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Ferriprox</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Cruderan</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29079595">
<a name="29079595"></a>Botzenhardt S, Felisi M, Bonifazi D, et al. Long-term safety of deferiprone treatment in children from the Mediterranean region with beta-thalassemia major: the DEEP-3 multi-center observational safety study. <i>Haematologica</i>. 2018;103(1):e1-e4. doi:10.3324/haematol.2017.176065<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferiprone-pediatric-drug-information/abstract-text/29079595/pubmed" id="29079595" target="_blank">29079595</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12100170">
<a name="12100170"></a>Ceci A, Baiardi P, Felisi M, et al. The Safety and Effectiveness of Deferiprone in a Large-Scale, 3-Year Study in Italian patients. <i>Br J Haematol. </i>2002;118(1):330-336.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferiprone-pediatric-drug-information/abstract-text/12100170/pubmed" id="12100170" target="_blank">12100170</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12763939">
<a name="12763939"></a>Cohen AR, Galanello R, Piga A, et al. Safety and Effectiveness of Long-Term Therapy With the Oral Iron Chelator Deferiprone. <i>Blood.</i> 2003;102(5):1583-1587.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferiprone-pediatric-drug-information/abstract-text/12763939/pubmed" id="12763939" target="_blank">12763939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26861970">
<a name="26861970"></a>Diamantidis MD, Neokleous N, Agapidou A, et al. Iron chelation therapy of transfusion-dependent β-thalassemia during pregnancy in the era of novel drugs: is deferasirox toxic? <i>Int J Hematol</i>. 2016;103(5):537-544. doi:10.1007/s12185-016-1945-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferiprone-pediatric-drug-information/abstract-text/26861970/pubmed" id="26861970" target="_blank">26861970</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Ferriprox (deferiprone) 500 mg tablets [prescribing information]. Cary, NC: Chiesi USA Inc; November 2021.</div>
</li>
<li>
<div class="reference">
                  Ferriprox (deferiprone) 1,000 mg tablets [prescribing information]. Cary, NC: Chiesi USA Inc; November 2021.</div>
</li>
<li>
<div class="reference">
                  Ferriprox (deferiprone) oral solution [prescribing information]. Cary, NC: Chiesi USA Inc; November 2021.</div>
</li>
<li>
<div class="reference">
                  Ferriprox (deferiprone) tablets and oral solution [product monograph]. Woodbridge, Ontario, Canada: Chiesi Canada Corp; October 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ferriprox.5">
<a name="Ferriprox.5"></a>Ferriprox and Ferriprox MR (deferiprone) tablets and extended-release tablets [product monograph]. Woodbridge, Ontario, Canada: Chiesi Canada Corp; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29200160">
<a name="29200160"></a>Gomber S, Dabas A, Bagmar S, Madhu SV. Glucose homeostasis and effect of chelation on β cell function in children with β-thalassemia major. <i>J Pediatr Hematol Oncol</i>. 2018;40(1):56-59. doi:10.1097/MPH.0000000000001043<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferiprone-pediatric-drug-information/abstract-text/29200160/pubmed" id="29200160" target="_blank">29200160</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32470438">
<a name="32470438"></a>Maggio A, Kattamis A, Felisi M, et al. Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial. <i>Lancet Haematol</i>. 2020;7(6):e469-e478. doi:10.1016/S2352-3026(20)30100-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferiprone-pediatric-drug-information/abstract-text/32470438/pubmed" id="32470438" target="_blank">32470438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31876777">
<a name="31876777"></a>Nazir HF, Alshizawi M. Neutropenia and life-threatening agranulocytosis among children with β-thalassemia treated with oral iron chelators in a community with background of ethnic neutropenia. <i>J Pediatr Hematol Oncol</i>. 2020;42(8):e750-e755. doi:10.1097/MPH.0000000000001699<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferiprone-pediatric-drug-information/abstract-text/31876777/pubmed" id="31876777" target="_blank">31876777</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Neufeld EJ. Oral Chelators Deferasirox and Deferiprone for Transfusional Iron Overload in Thalassemia Major: New Data, New Questions. <i>Blood.</i> 2006;107(9):3436-41.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30858957">
<a name="30858957"></a>Origa R, Comitini F. Pregnancy in thalassemia. <i>Mediterr J Hematol Infect Dis</i>. 2019;11(1):e2019019. doi:10.4084/MJHID.2019.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferiprone-pediatric-drug-information/abstract-text/30858957/pubmed" id="30858957" target="_blank">30858957</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li></ol></div><div id="topicVersionRevision">Topic 131933 Version 65.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
